Diamond Hill Capital Management LLC Investment Advisor Invests $10.36 Million in Avantor, Inc. $AVTR

Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Avantor, Inc. (NYSE:AVTR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,046,390 shares of the company’s stock, valued at approximately $10,359,000.

Several other large investors have also recently modified their holdings of the business. Royal Bank of Canada increased its stake in shares of Avantor by 104.3% in the first quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock valued at $3,302,000 after buying an additional 104,022 shares during the period. Empowered Funds LLC lifted its stake in shares of Avantor by 40.3% in the first quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock worth $286,000 after acquiring an additional 5,075 shares during the period. Cetera Investment Advisers boosted its holdings in Avantor by 40.2% in the second quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock valued at $542,000 after acquiring an additional 11,543 shares during the last quarter. Quantbot Technologies LP bought a new stake in Avantor in the second quarter valued at approximately $232,000. Finally, Arrowstreet Capital Limited Partnership increased its position in Avantor by 214.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock valued at $1,670,000 after purchasing an additional 84,679 shares during the period. Institutional investors own 95.08% of the company’s stock.

Avantor Stock Performance

Shares of Avantor stock opened at $13.52 on Tuesday. The business’s fifty day simple moving average is $11.28 and its 200 day simple moving average is $9.55. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. Avantor, Inc. has a 12 month low of $7.26 and a 12 month high of $15.93. The firm has a market capitalization of $9.14 billion, a P/E ratio of -16.10, a price-to-earnings-growth ratio of 10.29 and a beta of 0.89.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The firm had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, analysts anticipate that Avantor, Inc. will post 0.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AVTR. Stifel Nicolaus increased their price target on Avantor from $8.00 to $15.00 and gave the stock a “hold” rating in a report on Thursday, July 30th. Barclays increased their price target on Avantor from $7.00 to $8.00 and gave the stock an “underweight” rating in a report on Wednesday, June 24th. UBS Group set a $8.00 price objective on Avantor in a research note on Wednesday, June 24th. Wolfe Research upgraded Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, July 30th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Avantor in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $12.00.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.